Fate Therapeutics (FATE) PT Raised to $21.00 at Wedbush

Share on StockTwits

Fate Therapeutics (NASDAQ:FATE) had its target price boosted by research analysts at Wedbush from $19.00 to $21.00 in a research report issued on Monday. The brokerage currently has an “outperform” rating on the biopharmaceutical company’s stock. Wedbush’s price target would suggest a potential upside of 36.45% from the stock’s current price.

Several other equities analysts have also recently weighed in on FATE. Jefferies Financial Group initiated coverage on Fate Therapeutics in a report on Monday, November 5th. They set a “buy” rating and a $17.00 price objective on the stock. BidaskClub upgraded Fate Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Wednesday, December 5th. Stephens cut Fate Therapeutics from an “overweight” rating to an “equal” rating in a report on Thursday, January 3rd. Finally, Zacks Investment Research cut Fate Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, January 7th. One analyst has rated the stock with a sell rating, three have issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $18.86.

Shares of NASDAQ:FATE traded up $1.32 during trading on Monday, hitting $15.39. 18,943 shares of the company’s stock traded hands, compared to its average volume of 584,804. Fate Therapeutics has a 52 week low of $7.60 and a 52 week high of $17.98. The company has a debt-to-equity ratio of 0.07, a current ratio of 9.44 and a quick ratio of 9.44. The stock has a market capitalization of $908.92 million, a PE ratio of -15.09 and a beta of 2.06.

In related news, Director Amir Nashat sold 82,528 shares of Fate Therapeutics stock in a transaction that occurred on Tuesday, December 11th. The stock was sold at an average price of $16.71, for a total value of $1,379,042.88. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, General Counsel Cindy Tahl sold 25,000 shares of Fate Therapeutics stock in a transaction that occurred on Monday, January 7th. The shares were sold at an average price of $16.00, for a total value of $400,000.00. Following the completion of the sale, the general counsel now directly owns 47,426 shares in the company, valued at approximately $758,816. The disclosure for this sale can be found here. In the last three months, insiders sold 469,026 shares of company stock worth $6,928,487. 9.89% of the stock is owned by insiders.

Large investors have recently bought and sold shares of the business. Redmile Group LLC boosted its stake in shares of Fate Therapeutics by 58.9% during the 3rd quarter. Redmile Group LLC now owns 10,576,363 shares of the biopharmaceutical company’s stock worth $172,289,000 after acquiring an additional 3,920,401 shares during the period. BlackRock Inc. boosted its stake in shares of Fate Therapeutics by 45.0% during the 4th quarter. BlackRock Inc. now owns 5,031,783 shares of the biopharmaceutical company’s stock worth $64,557,000 after acquiring an additional 1,562,252 shares during the period. Partner Fund Management L.P. bought a new position in shares of Fate Therapeutics during the 3rd quarter worth approximately $24,455,000. FMR LLC boosted its stake in shares of Fate Therapeutics by 15.3% during the 3rd quarter. FMR LLC now owns 7,637,402 shares of the biopharmaceutical company’s stock worth $124,413,000 after acquiring an additional 1,011,596 shares during the period. Finally, Victory Capital Management Inc. boosted its stake in shares of Fate Therapeutics by 150.1% during the 4th quarter. Victory Capital Management Inc. now owns 1,318,860 shares of the biopharmaceutical company’s stock worth $16,921,000 after acquiring an additional 791,540 shares during the period. 86.30% of the stock is currently owned by hedge funds and other institutional investors.

About Fate Therapeutics

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; FT500 induced pluripotent stem cells (iPSC)-derived NK cell product candidate for the treatment of advanced solid tumors; FT516 engineered iPSC-derived NK cell product candidate for the treatment of hematologic/solid tumors; and FT819 engineered chimeric antigen receptor 19 iPSC-derived T-cell product candidate for hematologic/solid tumors.

Featured Article: Asset Allocation and Your Retirement

Analyst Recommendations for Fate Therapeutics (NASDAQ:FATE)

Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Spring Bank Pharmaceuticals Inc  Given Average Recommendation of “Buy” by Brokerages
Spring Bank Pharmaceuticals Inc Given Average Recommendation of “Buy” by Brokerages
Glazer Capital LLC Cuts Holdings in TKK Symphony Acquisition Corporation Units
Glazer Capital LLC Cuts Holdings in TKK Symphony Acquisition Corporation Units
Glazer Capital LLC Takes $2.72 Million Position in Alberton Acquisition Corporation Units
Glazer Capital LLC Takes $2.72 Million Position in Alberton Acquisition Corporation Units
Natixis Advisors L.P. Reduces Stake in Atlantica Yield PLC
Natixis Advisors L.P. Reduces Stake in Atlantica Yield PLC
Natixis Advisors L.P. Has $3.16 Million Stake in Gentex Co.
Natixis Advisors L.P. Has $3.16 Million Stake in Gentex Co.
Kalos Management Inc. Decreases Holdings in Eli Lilly And Co
Kalos Management Inc. Decreases Holdings in Eli Lilly And Co


Leave a Reply

 
© 2006-2019 Zolmax.